Stockscreener 앱 받기
3.80
9.51%
0.33
시간 외 거래:
3.78
-0.02
-0.53%
Foghorn Therapeutics Inc 주식(FHTX)의 최신 뉴스
Brokerages Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Price Target at $13.17 - Defense World
Foghorn Therapeutics to Host Virtual Investor Event to Review Pi - GuruFocus
Foghorn Therapeutics to Host Virtual Investor Event to - GlobeNewswire
Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting - The Globe and Mail
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Bought by Wellington Management Group LLP - Defense World
Foghorn Therapeutics (NASDAQ:FHTX) Trading 4.1% Higher – Time to Buy? - Defense World
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares May Have Slumped 29% But Getting In Cheap Is Still Unlikely - simplywall.st
(FHTX) Technical Data - news.stocktradersdaily.com
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates - MSN
Trend Tracker for (FHTX) - news.stocktradersdaily.com
Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients (NASDAQ:FHTX) - Seeking Alpha
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of “Buy” by Brokerages - The AM Reporter
Foghorn Therapeutics Announces New Preclinical Data for - GlobeNewswire
Breakthrough Cancer Drug FHD-909 Reveals Powerful Combination Potential Against Lung Cancer - Stock Titan
Analysts Set Foghorn Therapeutics Inc. (NASDAQ:FHTX) Target Price at $13.17 - Defense World
2,029,383 Shares in Foghorn Therapeutics Inc. (NASDAQ:FHTX) Bought by Raymond James Financial Inc. - Defense World
Foghorn Therapeutics adjusts ATM offering to $100M By Investing.com - Investing.com Australia
Foghorn Therapeutics adjusts ATM offering to $100M - Investing.com
What is B. Riley’s Forecast for FHTX Q1 Earnings? - Defense World
Foghorn Therapeutics Reports Progress and Financial Stability - TipRanks
Rhumbline Advisers Purchases 3,049 Shares of Foghorn Therapeutics Inc. (NASDAQ:FHTX) - Defense World
Foghorn Therapeutics’ (FHTX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Promising Advancements and Strategic Collaborations Position Foghorn Therapeutics as a Strong Buy - TipRanks
Promising Potential of Foghorn Therapeutics’ FHD-909 Drives Buy Rating Amid Strategic Advances - TipRanks
Foghorn Therapeutics Inc. reports results for the quarter ended December 31Earnings Summary - TradingView
Foghorn Therapeutics 2024 Net Loss Narrows, Revenue Declines -- Shares Slipping Late - Marketscreener.com
Foghorn Therapeutics Continues Enrollment in Phase 1 Trial of First-in-Class SMARCA2 Inhibitor FHD-909 for NSCLC and Reports Strong Financial Outlook - Nasdaq
Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook - GlobeNewswire
Can Foghorn's $243M War Chest Transform Cancer Treatment? Key Pipeline Updates - StockTitan
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know - MSN
Institutional investors may adopt severe steps after Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) latest 14% drop adds to a year losses - Yahoo
Foghorn Therapeutics (FHTX) Projected to Post Quarterly Earnings on Thursday - Defense World
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - GlobeNewswire
Can Foghorn's Gene Traffic Control Platform Impress Investors at Upcoming Healthcare Conferences? - StockTitan
How To Trade (FHTX) - Stock Traders Daily
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Optimistic Investors Push Foghorn Therapeutics Inc. (NASDAQ:FHTX) Shares Up 29% But Growth Is Lacking - Simply Wall St
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health – Company Announcement - Financial Times
Foghorn Therapeutics (FHTX) Loses -23.05% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
FHTX Stock Price and Chart — NASDAQ:FHTX - TradingView
Foghorn Therapeutics (FHTX) Soars 11.4%: Is Further Upside Left in the Stock? - MSN
Layoff Tracker: Q32, Inventiva, Third Harmonic Cut Staff - BioSpace
Eagle financial services executive buys $3,200 in stock - MSN
CENX’s Stock Woes: Up 59.32% in 6 Months, Up 59.32% in Just 5 Days - The InvestChronicle
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Harmony Gold Mining Co Ltd ADR (HMY) Stock: A Study of the Market Performance - The News Heater
2.51%
자본화:
|
볼륨(24시간):